[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Cetina L, Rivera L, Hinojosa J, Poitevin A, Uribe J, López-Graniel C, Cantú D, Candelaria M, de la Garza J, Dueñas-González A: Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results. BMC Womens Health; 2006;6:3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results.
  • BACKGROUND: Globally, cervical cancer primarily affects socially disadvantaged women.
  • Five randomized trials were the foundation for adopting cisplatin-based chemotherapy during radiation as the standard of care for high-risk patients after primary radical hysterectomy who require adjuvant radiation and for locally advanced patients treated with definitive radiation.
  • METHODS: We reviewed the files of 294 patients with locally advanced cervical cancer who received radiation plus weekly cisplatin as routine management between 1999 to 2003, and analyzed treatment compliance, response rate, toxicity, and survival.
  • The majority of cases were squamous cell carcinoma (87.8%), and distribution according to International Federation of Gynecology and Obstetrics (FIGO) stage was as follows: IB2-IIA, 23%; IIB, 53.3%, and IIIB, 23%; there were only two IVA cases.
  • Overall, 96% of patients completed external beam, and intracavitary therapy.
  • CONCLUSION: Our results support use of chemoradiation with six weekly applications of cisplatin at 40 mg/m2 during external radiation for routine management of locally advanced cervical cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2001 Sep 8;358(9284):781-6 [11564482.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):192-7 [11319297.001]
  • [Cites] Cancer Treat Rev. 2003 Oct;29(5):389-99 [12972357.001]
  • [Cites] Cancer Treat Rev. 2003 Dec;29(6):471-88 [14585258.001]
  • [Cites] J Hum Hypertens. 2004 Jul;18(7):511-6 [15002001.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Jun;16(4):255-60 [15214649.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):814-21 [15465198.001]
  • [Cites] Anticancer Drugs. 2004 Sep;15(8):761-6 [15494637.001]
  • [Cites] Radiother Oncol. 1989 Jan;14(1):9-17 [2928558.001]
  • [Cites] J Nutr. 1994 Aug;124(8):1179-88 [8064368.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(4):293-308 [9225947.001]
  • [Cites] J Gen Intern Med. 1998 Jun;13(6):357-65 [9669564.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):383-7 [10684715.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1606-13 [10764420.001]
  • [Cites] Cancer Invest. 2000;18(6):584-90 [10923107.001]
  • [Cites] Diabetes. 2000 Sep;49(9):1399-408 [10969821.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):88-91 [11277656.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1361-5 [12873681.001]
  • (PMID = 16464243.001).
  • [ISSN] 1472-6874
  • [Journal-full-title] BMC women's health
  • [ISO-abbreviation] BMC Womens Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1420274
  •  go-up   go-down


2. Chan JK, Loizzi V, Burger RA, Rutgers J, Monk BJ: Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer; 2003 Feb 1;97(3):568-74
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis.
  • BACKGROUND: The purpose of this study was to evaluate the clinical and pathologic factors associated with survival in patients with neuroendocrine (NE) cervical carcinoma.
  • METHODS: All patients with NE cervical carcinoma diagnosed between 1979-2001 were identified from tumor registry databases at two hospitals.
  • The impact of clinical and pathologic risk factors on the survival of patients with small cell NE carcinoma of the cervix was evaluated using Kaplan-Meier life table analyses and log-rank tests.
  • RESULTS: Thirty-four patients (median age, 42 years) were diagnosed with neuroendocrine cervical carcinoma, which included 21 with International Federation of Gynecology and Obstetrics (FIGO) Stage I disease, 6 with FIGO Stage II disease, 5 with FIGO Stage III disease, and 2 with FIGO Stage IV disease.
  • Fourteen women received adjuvant therapy with pelvic radiation and/or cisplatin-based chemotherapy.
  • Ten women received primary radiotherapy with (n = 5) or without (n = 4) chemotherapy and the remaining patient refused therapy.
  • Women with early-stage (Stage I-IIA) disease had median survival rates of 31 months compared with 10 months in the advanced-stage (Stage IIB-IVB) group (P = 0.002).
  • In univariate analysis, advanced stage (P = 0.002), tumor size >2 cm (P = 0.02), margin involvement (P = 0.016), pure versus a mixed histologic pattern (P = 0.04), margin status (P = 0.016), and smoking (P = 0.04) were considered poor prognostic factors.
  • In multivariate analysis, smoking for early-stage patients and stage of disease in the overall population remained as independent prognostic factors of survival.
  • CONCLUSIONS: Smoking and advanced stage are reported to be poor prognostic factors for survival in patients with NE small cell carcinoma of the cervix.
  • The role of primary or postoperative radiation with or without chemotherapy is unclear and yields uniformly poor results, particularly in patients with advanced lesions.
  • [MeSH-major] Carcinoma, Small Cell / mortality. Uterine Cervical Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11086
  • (PMID = 12548598.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Kietpeerakool C, Lattiwongsakorn W, Srisomboon J: Incidence and predictors of febrile morbidity after radical hysterectomy and pelvic lymphadenectomy for early stage cervical cancer patients. Asian Pac J Cancer Prev; 2008 Apr-Jun;9(2):213-6
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and predictors of febrile morbidity after radical hysterectomy and pelvic lymphadenectomy for early stage cervical cancer patients.
  • Patients with FIGO stage IB-IIA cervical cancers who had undergone RHPL at Chiang Mai University Hospital between January 2003 and December 2005, were reviewed.
  • The clinical variables including the age at diagnosis, menopausal status, body mass index, previous cervical conization, tumor size, preoperative chemotherapy, preoperative anemia, operative time, and estimated blood loss were analyzed for prediction of postoperative febrile morbidity.
  • The majority of women (77.3%) were in FIGO stage IB1.
  • The most common histology was squamous cell carcinoma (69.2%).
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Fever / etiology. Hysterectomy / adverse effects. Lymph Node Excision / adverse effects. Postoperative Complications. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Blood Loss, Surgical. Female. Humans. Incidence. Middle Aged. Risk Factors. Surgical Wound Infection / epidemiology. Surgical Wound Infection / etiology. Surgical Wound Infection / prevention & control. Treatment Outcome. Urinary Tract Infections / epidemiology. Urinary Tract Infections / etiology. Urinary Tract Infections / prevention & control


Advertisement
4. Kim JS, Kim JS, Kim SY, Kim Ki, Cho MJ: Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1247-53
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.
  • PURPOSE: To evaluate efficacy, toxicity, and patterns of relapse in patients treated with hyperfractionated radiotherapy (HFRT) with concurrent chemotherapy for para-aortic lymph node (PALN) recurrence of cervical carcinoma.
  • METHODS AND MATERIALS: Between September 1997 and October 2000, 12 cervical carcinoma patients with isolated PALN recurrence who had previously received radical or postoperative radiotherapy were treated with HFRT and concurrent chemotherapy.
  • The initial FIGO stage was Stage IB in 4 (33%) patients, Stage IIA in 2 (17%), and Stage IIB in 6 (50%).
  • The fractionated dose was 1.2 Gy in 2 daily fractions, and the median total dose was 60 Gy.
  • The weekly concurrent chemotherapy consisted of paclitaxel in 11 patients and cisplatin in 1.
  • The median number of cycles of chemotherapy was 5.
  • RESULTS: The latent period to PALN recurrence from the time of initial treatment for all patients ranged from 2 to 92 months (median: 12 months).
  • One month after treatment, the clinical tumor response evaluated was complete in 33% (4/12) and partial in 67% (8/12).
  • The latent period to PALN recurrence was the only significant prognostic factor; the median survival of patients who relapsed in < or =24 months from the initial treatment of cervical carcinoma was 13 months vs. 45 months for those relapsed at >24 months (p = 0.026).
  • Grade 3-4 hematologic toxicity developed in 2 patients.
  • Subsequent distant metastases after PALN treatment developed in 58% (7/12).
  • CONCLUSION: HFRT of 60 Gy to PALN with concurrent chemotherapy could be regarded as an effective treatment modality without significant acute or late toxicity.
  • Patients with a latent period >24 months until PALN recurrence had a more favorable survival rate than those with a latent period </=24 months.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brachytherapy. Carcinoma, Squamous Cell / secondary. Cisplatin / therapeutic use. Lymphatic Irradiation. Lymphatic Metastasis / radiotherapy. Paclitaxel / therapeutic use. Radiotherapy, High-Energy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic / adverse effects. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / secondary. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Hematologic Diseases / etiology. Humans. Hysterectomy. Life Tables. Middle Aged. Nausea / etiology. Neoplasm Metastasis. Radiation Injuries / etiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12654434.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 29
  •  go-up   go-down


5. Mossa B, Mossa S, Marziani R: Adjuvant chemotherapy versus radiation therapy after radical surgery in high-risk positive node stage IB/IIA cervical cancer. Eur J Gynaecol Oncol; 2010;31(5):545-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy versus radiation therapy after radical surgery in high-risk positive node stage IB/IIA cervical cancer.
  • OBJECTIVE: The aim of this study was to evaluate whether the addition of adjuvant chemotherapy will improve the outcomes of high-risk patients with Stage IB, IIA squamous cervical carcinoma with positive pelvic and/or aortic nodes.
  • MATERIALS AND METHODS: 127 patients with Stage IB and IIA cervical carcinoma treated with radical hysterectomy and systematic pelvic/aortic lymphadenectomy (RS) and who had lymph node involvement, confirmed at the final histological examination were enrolled from January 1987 to December 2001.
  • All the patients received three cycles of adjuvant chemotherapy (AC) with cisplatin, bleomycin and vinblastine.
  • Seventy-seven patients had FIGO Stage IB1, 26 IB2 and 24 IIA.
  • The results were compared with those obtained from a group of 136 patients with comparable age, stage and lymph node involvement, on whom radical surgery, systematic pelvic/aortic lymphadenectomy (RS) and adjuvant radiotherapy (RT) was performed on period 1971-1984.
  • CONCLUSIONS: Adjuvant chemotherapy in high-risk patients for lymph node positivity did not produce statistically significant results in terms of overall and disease-free survival vs adjuvant radiotherapy; however, a group of these patients, approximately 10%, could receive benefit from the treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Sentinel Lymph Node Biopsy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Case-Control Studies. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant


6. Hänsgen G, Dunst J: [Adjuvant radio- and chemotherapy in cervix carcinoma]. Zentralbl Gynakol; 2001 May;123(5):280-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant radio- and chemotherapy in cervix carcinoma].
  • [Transliterated title] Adjuvante Radio- und Chemotherapie beim Zervixkarzinom.
  • The screening for cervical cancer has been reduced both the incidence of and mortality from invasive cervical cancer in the western world.
  • Radical pelvic surgery is an effective treatment for early invasive cervical cancer (FIGO-stage IB and IIA), but for woman with more advanced disease radiotherapy is the standard treatment.
  • However, the survival of the cervical cancer patients has not been improved over the last decade.
  • Previous studies have suggested that chemotherapy and radiotherapy are synergistic.
  • The results of five large studies have shown that cisplatin-based chemotherapy when given at the same time a radiation therapy, prolongs survival in woman with cervical cancer.
  • This was also observed in primary treatment schedule as in adjuvant situation.
  • The results suggest that chemoradiation is the favorable therapy for cervical cancer in advanced stage and in high-risk-situation.
  • [MeSH-major] Adenocarcinoma / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11449621.001).
  • [ISSN] 0044-4197
  • [Journal-full-title] Zentralblatt für Gynäkologie
  • [ISO-abbreviation] Zentralbl Gynakol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. de la Rochefordiere A, Kirova Y, Alran S, Plancher C, Fourchotte V, Beuzeboc P, de Margerie V, Petrow P, Sastre-Garau X, Servois V, Scholl S, Cottu P, Mignot L, de Cremoux P, Salmon R: Pre-operative Concomitant Radio-chemotherapy in Bulky Carcinoma of the Cervix: A Single Institution Study. Clin Med Oncol; 2008;2:227-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-operative Concomitant Radio-chemotherapy in Bulky Carcinoma of the Cervix: A Single Institution Study.
  • OBJECTIVE: To evaluate the treatment results of patients (pts) with FIGO stage IB2, IIA, IIB cervical carcinoma (CC) treated with pre-operative radio-chemotherapy, followed by extended radical hysterectomy.
  • METHODS: Retrospective study of 148 women treated to the Institut Curie for operable FIGO Stage IB2 to IIB, biopsy proved CC.
  • Among them, 70 pts, median age 46 years, were treated using the same regimen associating primary radio-cisplatinum based chemotherapy, intracavitary LDR brachytherapy, followed by extended radical hysterectomy.
  • Residual macroscopic or microscopic disease in the cervix was observed in 28 pts (40%).
  • Seventeen pts (25%) had residual cervix disease but negative nodes.
  • IN CONCLUSION: The treatment of locally advanced CC needs a new multidisciplinary diagnostic and treatment approach using new therapeutic arms to improve the survival and treatment tolerance among women presenting this disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] Gynecol Oncol. 2007 Jan;104(1):15-23 [16996583.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2055-60 [10561258.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1606-13 [10764420.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):324-8 [10985888.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):179-88 [11773168.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Gynecol Oncol. 1989 May;33(2):225-30 [2467848.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):218s-223s [12743138.001]
  • [Cites] Radiother Oncol. 2003 Sep;68(3):217-26 [13129628.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):872-80 [14990643.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8289-95 [16230678.001]
  • [Cites] Gynecol Oncol. 2006 Sep;102(3):523-9 [16504274.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • (PMID = 21892284.001).
  • [ISSN] 1177-9314
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3161687
  • [Keywords] NOTNLM ; brachytherapy / cervix cancer / chemotherapy / radical hysterectomy / radiotherapy / treatment
  •  go-up   go-down


8. Bader AA, Petru E, Winter R: Long-term follow-up after neoadjuvant chemotherapy for high-risk cervical cancer during pregnancy. Gynecol Oncol; 2007 Apr;105(1):269-72
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up after neoadjuvant chemotherapy for high-risk cervical cancer during pregnancy.
  • BACKGROUND: We report on a patient with a high-risk cervical cancer during pregnancy treated with neoadjuvant chemotherapy (NACT) followed by radical surgery.
  • CASE: A 38-year-old woman was diagnosed with FIGO stage IIA cervical cancer at 19 weeks' gestation.
  • Histology showed a poorly differentiated squamous cell carcinoma with lymph vascular invasion and pelvic lymph node metastases.
  • The patient received three further cycles of chemotherapy.
  • CONCLUSION: NACT followed by radical surgery may be effective in selected patients with invasive cervical cancer during pregnancy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Pregnancy Complications, Neoplastic / drug therapy. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Cesarean Section. Cisplatin / administration & dosage. Female. Humans. Hysterectomy. Lymph Node Excision. Neoadjuvant Therapy. Neoplasm Staging. Pregnancy. Risk Factors. Vincristine / administration & dosage


9. Cheng X, Cai SM, Li ZT, Wu XH, Ding YQ, Wang XE, Zang RY: Concurrent chemotherapy and adjuvant extended field irradiation after radical surgery for cervical cancer patients with lymph node metastases. Int J Gynecol Cancer; 2008 Jul-Aug;18(4):779-84
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemotherapy and adjuvant extended field irradiation after radical surgery for cervical cancer patients with lymph node metastases.
  • The purpose of this retrospective study was to report our experience with concurrent chemotherapy and adjuvant extended field irradiation after radical surgery for cervical carcinoma patients with common iliac node and/or multiple pelvic lymph nodes metastases.
  • We studied 25 patients with FIGO stage IB-IIB (IB, 3; IIA, 15; and IIB, 7) cervical carcinoma who underwent radical surgery and had histologically confirmed involvement of common iliac nodes and/or multiple (>or=2) pelvic lymph nodes.
  • These patients received the first cycle of systemic chemotherapy 2 weeks after radical surgery.
  • Then, they received pelvic and extended field irradiation (40-45 Gy) with weekly cisplatinum (30 mg/m(2)).
  • They were then given five more cycles of consolidation chemotherapy.
  • No patient's treatment failed in the para-aortic region.
  • Concurrent chemotherapy and adjuvant extended field irradiation after radical surgery achieved good local control with acceptable toxicity.
  • However, subsequent distant metastasis was still the predominant form of treatment failure even after consolidation chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Hysterectomy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Brachytherapy / methods. Chemotherapy, Adjuvant / adverse effects. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Radiotherapy, Adjuvant / adverse effects. Recurrence. Retrospective Studies

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17944922.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Srivastava K, Singh S, Srivastava M, Srivastava AN: Incisional skin metastasis of a squamous cell cervical carcinoma 3.5 years after radical treatment--a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1183-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incisional skin metastasis of a squamous cell cervical carcinoma 3.5 years after radical treatment--a case report.
  • Metastatic carcinoma in an abdominal wall incision from internal malignant neoplasm is an uncommon and often a preterminal event.
  • Incisional metastasis from postoperative case of carcinoma cervix is very rare.
  • We report a postoperative case of squamous cell carcinoma cervix FIGO stage IIA in a patient who after 3.5 years of completion of radical treatment (postoperative external and intravaginal radiation therapy) developed incisional skin metastasis followed by extensive subcutaneous metastasis in the vulval region.
  • She received salvage chemotherapy; however, she did not show any response and finally succumbed to the disease.
  • The intent of treatment remains palliation either by radiation/chemotherapy/surgery alone or in combinations.
  • As far as we know, this is the first case of squamous cell carcinoma cervix stage IIA having incisional scar recurrence 3.5 years after postoperative radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Fatal Outcome. Female. Fluorouracil / administration & dosage. Gynecologic Surgical Procedures. Humans. Radiotherapy


11. Kirova YM, Bourhaleb Z, Alran S, Campitelli M, Plancher C, Fourchotte V, Beuzeboc P, Petrow P, Cottu P, de Cremoux P, Sastre-Garau X, de la Rochefordière A: [Preoperative concomitant radiochemotherapy in bulky carcinoma of the cervix: Institut Curie experience]. Cancer Radiother; 2009 Jul;13(4):291-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative concomitant radiochemotherapy in bulky carcinoma of the cervix: Institut Curie experience].
  • PURPOSE: To evaluate the treatment results of patients (pts) with Figo stage IB2, IIA, IIB cervical carcinoma (CC) treated with preoperative radiochemotherapy, followed by extended radical hysterectomy.
  • PATIENTS AND METHODS: Retrospective study of 148 women treated at the Institut Curie for operable Figo Stage IB2 to IIB, biopsy proved CC.
  • Among them, 70 pts, median age 46 years, were treated using the same regimen associating primary radiocisplatinum based chemotherapy, intracavitary LDR brachytherapy, followed by extended radical hysterectomy.
  • Residual macroscopic or microscopic disease in the cervix was observed in 28 pts (40%).
  • Seventeen pts (25%) had residual cervix disease but negative nodes.
  • CONCLUSION: The treatment of locally advanced CC needs a new multidisciplinary diagnostic and treatment approach using new therapeutic arms to improve the survival and treatment tolerance among women presenting this disease.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brachytherapy / methods. Cancer Care Facilities. Combined Modality Therapy / methods. Female. France. Humans. Hysterectomy / methods. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Remission Induction. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19524469.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. King M, McConkey C, Latief TN, Hartley A, Fernando I: Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin Oncol (R Coll Radiol); 2006 Feb;18(1):38-45
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects.
  • AIMS: A recent meta-analysis has shown a survival advantage for the addition of concurrent chemotherapy to radiotherapy in the treatment of cervical carcinoma.
  • Controversy persists about the most appropriate chemotherapy schedule and whether similar results for tumour control and toxicity may be achieved with optimally delivered radiotherapy.
  • A single-centre experience of a concurrent chemotherapy regimen is presented.
  • Acute and late complications were scored using the National Cancer Institute Common Toxicity Criteria and RTOG/ EORTC system, respectively.
  • Univariate and multivariate analyses were carried out to examine the relationship between demographics, stage, overall treatment time, radiotherapy dose, selectron insertion, number of chemotherapy cycles and occurrence of acute and late toxicity.
  • Thirty-eight per cent had early tumours (FIGO IIA or less) and 62% had locally advanced tumours.
  • Twenty-eight per cent of women had surgery as part of primary treatment.
  • Radiation technique included external-beam pelvic radiotherapy (EBRT) (45-50.4 Gy in 25-28 fractions) and medium-dose rate brachytherapy single insertion (25-27 Gy to point A) or EBRT alone.
  • Median overall treatment time was 49 days (range 23-91 days).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Radiation Injuries / etiology. Radiotherapy / adverse effects. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Oncol (R Coll Radiol). 2006 Sep;18(7):576-7 [16969993.001]
  • [ErratumIn] Clin Oncol (R Coll Radiol). 2006 May;18(4):368
  • (PMID = 16477918.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Mancebo G, Gil-Moreno A, Vergés R, Martínez-Palones JM, Checa MA, Carreras JM, Giralt J, Xercavins J: Out-of-protocol concurrent use of cisplatin and radiation therapy in locally advanced cervical cancer: feasibility and survival. Eur J Gynaecol Oncol; 2010;31(1):18-22
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Out-of-protocol concurrent use of cisplatin and radiation therapy in locally advanced cervical cancer: feasibility and survival.
  • PURPOSE OF INVESTIGATION: We assessed the feasibility, response rates, and overall survival of patients with locally advanced cervical cancer treated with cisplatin-based chemotherapy during radiation therapy on an out-of-protocol basis.
  • METHODS: Sixty-nine consecutive newly diagnosed untreated patients with locally advanced cervical cancer who received chemoradiation between 1999 and 2003 were retrospectively reviewed.
  • Treatment consisted in external beam radiation followed by one 137-cessium intracavitary application.
  • RESULTS: Treatment was well tolerated, although 52 patients presented some degree of acute adverse toxicity (gastrointestinal 65%, hematological 48%, genitourinary 10%).
  • The 3-year survival rate was 61.8% (95% CI 54.5-69.0), with a mean 41.8 months (95% CI 35.7-48.3).
  • Overall survival after adjusting by FIGO Stage IB2-IIA and IIB-IVA was 73.9% and 50%, respectively (p = 0.1839).
  • CONCLUSION: In patients with locally advanced cervical cancer, adding a weekly regimen of cisplatin to standard pelvic radiation in an out-of-protocol basis is feasible, effective, and showed no unexpected toxicity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Brachytherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Female. Humans. Middle Aged. Prognosis. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349775.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Reimer D, Sztankay A, Steppan I, Abfalter E, Lunzer H, Marth C, Zeimet AG: Cervical cancer associated with genital prolapse--a brief review of the literature and long-term results of successful treatment with radiochemotherapy and surgery in a very frail patient. Eur J Gynaecol Oncol; 2008;29(3):272-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical cancer associated with genital prolapse--a brief review of the literature and long-term results of successful treatment with radiochemotherapy and surgery in a very frail patient.
  • BACKGROUND: A case of cervical cancer associated with irreducible procidentia successfully treated with external beam radiation and extracorporeal HDR-AL with concomitant chemotherapy followed by obliterative vaginal surgery is reported for the first time.
  • CASE: A 73-year-old woman presented in frail condition suffering from a huge, irreducible uterovaginal procidentia combined with a squamous cell carcinoma of the cervix in FIGO Stage IIa.
  • Successful treatment consisted of sequential application of combined radiotherapy with concurrent cisplatin chemotherapy followed by total vaginal hysterectomy and partial colpectomy with colpocleisis according to the Labhardt method.
  • The five-year follow-up documents the excellent long-term results with regard to cervical cancer and pelvic floor stability.
  • CONCLUSION: Especially in patients ineligible for extended surgery, radiochemotherapy followed by an obliterative surgical approach is feasible without aberrant wound healing and constitutes a suitable and efficient option for treating carcinomas of the cervix associated with irreducible genital prolapse.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Cisplatin / therapeutic use. Uterine Cervical Neoplasms / therapy. Uterine Prolapse / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Frail Elderly. Humans. Hysterectomy, Vaginal. Neoadjuvant Therapy. Radiotherapy, Adjuvant


15. Tsubamoto H, Wada R, Kanazawa R, Komori S, Maeda H, Hirota S, Adachi S: Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16518

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma.
  • : e16518 Background: Adenocarcinoma (including adenosquamous carcinoma) of the uterine cervix has a tendency to early lymph node metastasis and is resistant to radiation therapy, thus results in poor prognosis compared with squamous cell carcinoma.
  • Neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) for bulky cervical adenocarcinoma seems to be an alternative therapy to primary radiation.
  • Eligible criteria were as follows: Histologically diagnosed cervical adeno or adenosquamous carcinoma with FIGO stage IB2-IVA, Age < or equal to 75, PS 0-2, given informed consent.
  • The NAC regimen consisted of paclitaxel (60mg/m2, iv, D1, D8, D15) and cisplatin (70 mg/m2, trans-uterine arterial infusion followed by embolization using the gelform, D2) repeated every 3 weeks for 2-3 cycles, followed by RH.
  • RESULTS: Enrolled patients: 22 (1998-2006), Age: median 51 (33-75), FIGO stage: IB2 (9), IIA-IIB (8), IIIB (3), IVA (2), adeno/adenosquamous: 16/6.
  • Clinical response rate (RR: CR+PR) of the patients with stage IB2-IIB was 100%.
  • RR of the patients with stage IIIb-IVa was 80%, three patients completed RH with either modified anterior or posterior exenteration, and pCR was found in one patient.
  • The rate of radiation therapy following either NAC or surgery among enrolled patients were 18% (3/17) with stage IB2-IIB and 40% (2/5) with IIIB-IVA.
  • 5 year RFS/OS were 69%/68% with stage IB2-IIb and 60%/60% with stage IIIb-IVa.
  • One patient with stage IVa had urostomy, and other 14 patients have no trouble in urination function.
  • CONCLUSIONS: TACE with cisplatin and dose dense paclitaxel in the neoadjuvant setting is feasible and effective for cervical adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Niibe Y, Ariga T, Kazumoto T, Kodaira T, Etou H, Suzuki O, Kinoshita R, Tsujino K, Takemoto M, Hayakawa K: Curative intended radiation therapy for young patients with invasive uterine cervical carcinoma: Clinical outcomes in 105 patients in a Japanese multi-institutional study. J Clin Oncol; 2009 May 20;27(15_suppl):e16558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative intended radiation therapy for young patients with invasive uterine cervical carcinoma: Clinical outcomes in 105 patients in a Japanese multi-institutional study.
  • : e16558 Background: Recently, the number of young patients with invasive uterine cervical carcinoma is increasing in Japan because of earlier sexual activity and low rate of receiving screening test of uterine cervical carcinoma in Japan.
  • However, no large studies have been performed so far to evaluate the clinical outcomes of curative intended radiation therapy for young patients with invasive uterine cervical carcinoma in Japan.
  • According to FIGO, clinical stage was as follows.
  • Stage Ib/IIa/IIb/IIIa/IIIb/IVa were 10/4/38/2/47/3, respectively.
  • Curative intended radiation therapy was the combination of high-dose rate intracavitary brachytherapy (HDR-ICBT) combined with external beam radiation therapy (ERT).
  • The total dose of ERT ranged from 44 Gy to 68 Gy.
  • The total dose of HDR-ICBT to point A ranged from 12 Gy to 48 Gy.
  • Eighty five patients received chemotherapy.
  • The 5-year overall survival rates of stage Ib/IIa/IIb/IIIa/IIIb/IVa were 90.0 %/not available (NA)/73.8%/100%/37.4%/0%, respectively.
  • The 5-year local control rates of Stage Ib/IIa/IIb/IIIa/IIIb/IVa were 80.0 %/50.0 %/73.8 %/100 %/54.6 %/NA, respectively.
  • CONCLUSIONS: Clinical outcomes of stage I-II in the young were equivalent to the Japanese standard treatment results of all ages.
  • However, clinical outcomes of stage IIIb and IVa in the young were worse than those of all ages (5-year OS of all ages in Japan: IIIb: 50 %, IVa: 25 %).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960807.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Marinaccio M, De Marino E, Mele E, Catacchio R, Pellegrino C, Pinto V, Schonauer S: Paclitaxel, ifosfamide, and cisplatin regimen as neoadjuvant chemotherapy in young women with locally advanced squamous cervical cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5587

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel, ifosfamide, and cisplatin regimen as neoadjuvant chemotherapy in young women with locally advanced squamous cervical cancer.
  • : 5587 Background: Chemoradiotherapy is the standard treatment of advanced cervical cancer.
  • Neoadjuvant chemotherapy (NAC) may represent an alternative for locally advanced cervical cancer (LACC).This study was undertaken to evaluate the efficacy of NAC in young patients with squamous LACC.
  • Eligibility included proven histologically diagnosis of squamous cervical carcinoma, FIGO stage IB2/IIA>4cm/IIB, measurable disease, ECOG PS 0-2, no prior therapy and age under 49 years.
  • RESULTS: 35pts (57.4%) were stage IB2; 9 (14.7%) were IIA >4cm; and 17 (27.9%) were IIB.
  • Out of 55 pts, 50 received 2 cycles of TIP regimen as a consolidation therapy before follow-up; 5 pts with incomplete pPR underwent radio/chemoradiotherapy.
  • CONCLUSIONS: Our results indicate that TIP regimen-based NAC is an attractive option in young women with squamous LACC (IB2,IIA >4cm, IIB) that strongly desire surgery.The rate of patients with a prolonged remission of disease (82.0%) suggests that the clinical benefit of TIP regimen-based NAC followed by surgery may be comparable to chemoradiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962390.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Dangal G: Surgical treatment for early cervical cancer: Experience at a cancer hospital in Nepal. J Clin Oncol; 2009 May 20;27(15_suppl):e16575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for early cervical cancer: Experience at a cancer hospital in Nepal.
  • : e16575 Background: The purpose of this study was to find out the clinocopathologic characteristics, post-operative findings and complications of patients with early (up to stage IIA) cervical carcinoma who underwent radical hysterectomy.
  • This study concentrates on the evaluation of our early experience in radical hysterectomy for cervical cancer in Nepal.
  • METHODS: This was a retrospective analysis of 48 patients who had radical hysterectomy with bilateral pelvic lymphadenectomy for early cervical cancer at the BP Koirala Memorial Cancer Hospital (BPKMCH) from September 2002 through September 2005.
  • More than half of them (56%) had FIGO stage IIA disease.
  • Forty-four had squamous cell carcinoma and four had adenocarcinoma.
  • Majority (62.5%) of the women were premenopausal and 56% of them had stage IIA disease.
  • CONCLUSIONS: Although the primary treatment of early-stage cervical carcinoma involves either surgery or radiation therapy with or without chemotherapy, surgery (radical hysterectomy) was used for lower-stage disease and smaller lesions in fit and young patients in our resource-poor set-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Chumworathayi B, Suprasert P, Charoenkwan K, Srisomboon J, Phongnarisorn C, Siriaree S, Cheewakriangkrai C, Tantipalakorn J, Kiatpeerakul C, Pantusart A: Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: a randomized comparison of treatment compliance. J Med Assoc Thai; 2005 Nov;88(11):1483-92
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: a randomized comparison of treatment compliance.
  • OBJECTIVES: To compare weekly and three-weekly cisplatin as an adjunct to radiation therapy in high-risk early-stage cervical cancer after surgery with regard to treatment compliance.
  • MATERIAL AND METHOD: From June 1st, 2003 to February 29th, 2004, the authors performed a randomized trial of radiotherapy in combination with two concurrent chemotherapy regimens - weekly or three-weekly cisplatin--in patients with high-risk cervical cancer FIGO stage I-IIA after surgery.
  • Women with primary invasive squamous-cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix were enrolled.
  • Patients were randomly assigned to receive one of two chemotherapy regimens: 75 mg per square meter of cisplatin on days 1, 22, 43 and 64 or every three weeks for 4 cycles (group 1) or 40 mg per square meter of cisplatin per week for six cycles (group 2).
  • The first group that received three-weekly cisplatin had a higher rate of incomplete and delayed treatments than the second group that received weekly cisplatin (p < 0.001 and p = 0.0236 respectively).
  • The toxicity-related incomplete treatments rate and G-CSF doses used were significantly higher in group 1 than in group 2.
  • CONCLUSION: Concurrent chemoradiation with weekly cisplatin regimen has more complete treatment rate and less delayed courses than that with three- weekly cisplatin among women with high-risk cervical cancer after surgery.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Patient Compliance. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Risk Assessment. Time Factors


20. Pérez-Regadera J, Sánchez-Muñoz A, De-la-Cruz J, Ballestín C, Lora D, García-Martín R, Alonso-Carrión L, Mendiola C, Lanzós E: Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer. Int J Gynecol Cancer; 2010 Jan;20(1):164-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer.
  • OBJECTIVES: To determine the impact of c-erb-B2 overexpression on disease-free survival (DFS) and local relapse in patients with advanced cervical cancer (CC) receiving concurrent chemoradiotherapy treatment.
  • METHODS: A total of 136 patients with advanced CC (FIGO stage: IB2-IIA [12]; IIB [34]; IIIB [71]; IVA [19]; including both epidermoid [86] and adenocarcinoma [14]) were analyzed to determine c-erb-B2 levels by immunohistochemistry (c-erb-B2 antibody; Dako, Glostrup, Denmark).
  • All patients received pelvic radiotherapy, brachytherapy, and concurrent chemotherapy with 2 different regimens: 48 patients were treated with tegafur (800 mg/d orally) and 88 with tegafur (same doses) plus 5 cycles of weekly cisplatin 40 mg/m/wk intravenously.
  • The group of patients with c-erb-B2 overexpression that did not receive platinum treatment had a higher rate of pelvic relapse (P < 0.0001), associated with a decreased DFS (P = 0.0014).
  • Treatment with cisplatin-based radiochemotherapy improved outcome in these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Tegafur / administration & dosage. Treatment Outcome. Up-Regulation


21. Mayer A, Nemeskéri C, Petneházi C, Borgulya G, Varga S, Naszály A: Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens. Strahlenther Onkol; 2004 Apr;180(4):209-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens.
  • BACKGROUND: Comprehensive literature on cervical cancer demonstrates, even today, the need for optimization of the timing of external-beam radiotherapy (EBRT) and high-dose-rate brachytherapy (HDR-BT) in the treatment of stage IIA/B-IIIB cervical carcinoma.
  • PATIENTS AND METHODS: 210 patients with carcinoma of the cervix were treated in the Municipal Center of Oncoradiology between January 1991 and December 1996 (FIGO IIA: n = 10, FIGO IIB: n = 113, and FIGO IIIB: n = 87).
  • Two regimens were compared: sequential radiation therapy (SRT) with 4 x 8 Gy HDR-BT to point A followed by EBRT, and continuous radiation therapy (CRT) in which 5 x 6 Gy HDR-BT to point A, one session per week, was integrated into the EBRT.
  • A total dose of 68-70 Gy to point A and 52-54 Gy to point B was given in EBRT with SRT, five fractions per week were applied.
  • Overall treatment time (OTT) amounted to 56 days for SRT and 35 days for CRT.
  • Median follow-up time was 3.4 (2.5-4.2) years.
  • The dose of 8 Gy per fraction of HDR-BT in the SRT regimen was obviously too high.
  • To achieve a significant improvement in local control and disease-free survival (DFS) as well as overall survival (OS), the combination with modern chemotherapy regimens and regional deep hyperthermia may rather be the treatment option.
  • [MeSH-major] Brachytherapy. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Cervix Uteri / pathology. Confidence Intervals. Cystoscopy. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Neoplasm Staging. Proportional Hazards Models. Radiography, Abdominal. Radiotherapy Dosage. Regression Analysis. Survival Analysis. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Strahlenther Onkol. 2005 Jan;181(1):54 [15660194.001]
  • (PMID = 15057431.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Lee JM, Lee KB, Nam JH, Ryu SY, Bae DS, Park JT, Kim SC, Cha SD, Kim KR, Song SY, Kang SB: Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol; 2008 Feb;19(2):321-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study.
  • BACKGROUND: To determine the clinical and pathologic prognostic factors in surgically treated patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix (SCNEC).
  • PATIENTS AND METHODS: We retrospectively reviewed a total of 68 patients with FIGO stage IB-IIA SCNEC surgically treated from January 1997 to December 2003 in Korea.
  • RESULTS: Of the 68 patients, 43 had FIGO stage IB1 SCNEC, 15 had stage IB2, and 10 had stage IIA.
  • Seven were treated with radical surgery alone; 11 with neoadjuvant chemotherapy (NACT) followed by radical surgery; 24 with radical surgery followed by adjuvant chemotherapy; and 26 with radical surgery followed by adjuvant radiation or chemoradiation.
  • Univariate and multivariate analysis showed that FIGO stage was predictive of poor prognosis.
  • Adjuvant chemoradiation did not improve survival compared with adjuvant chemotherapy alone.
  • CONCLUSIONS: FIGO stage may act as a surrogate for factors prognostic of survival.
  • Primary radical surgery followed by adjuvant chemotherapy is the preferred treatment modality for patients with early stage SCNEC.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962205.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


23. Boruta DM 2nd, Schorge JO, Duska LA, Crum CP, Castrillon DH, Sheets EE: Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix. Gynecol Oncol; 2001 Apr;81(1):82-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix.
  • OBJECTIVE: Patients with early-stage neuroendocrine cervical carcinoma (NECC) have a high mortality rate despite aggressive therapy.
  • The rarity of this tumor precludes initiation of a randomized, prospective trial.
  • We reviewed our experience in early stage disease and performed a meta-analysis of the literature to identify prognostic factors and determine optimal multimodality therapy.
  • METHODS: Eleven women with International Federation of Gynecology and Obstetrics (FIGO) early stage (IB--IIA) NECC were treated with surgery and chemotherapy at our institutions between 1978 and 1998.
  • Administration of radiation therapy was recorded, but not required for inclusion in this study.
  • Twenty-three early-stage NECC patients who were similarly treated during the study interval were identified by a Medline search of the English literature and included in the analysis.
  • Median cervical tumor diameter was 3.2 cm (range 0.5--11.0 cm).
  • Fifteen patients received postoperative platinum/etoposide (PE), seven received vincristine/adriamycin/cyclophosphamide (VAC), two received alternating cycles of VAC and PE, and ten received other chemotherapy regimens.
  • Twenty women were treated with radiation therapy.
  • PE and VAC chemotherapy was associated with increased survival (P < 0.01).
  • CONCLUSION: NECC is a highly lethal variant of cervical cancer.
  • [MeSH-major] Carcinoma, Neuroendocrine / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11277655.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CAV protocol; VP-P protocol
  •  go-up   go-down


24. Adachi S, Ogasawara T, Tsubamoto H, Oku H, Hori Y, Tsuji Y, Takemura T, Koyama K: Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer. Int J Clin Pharmacol Res; 2001;21(3-4):105-10
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer.
  • Nedaplatin is a platinum analog that has less renal toxicity and higher efficacy for uterine cervical cancer than cisplatin.
  • Intraarterial cisplatin has been shown to be more effective than intravenous cisplatin in the treatment of cervical cancer.
  • To improve the prognosis of cervical cancer, we studied combination chemotherapy of intravenous nedaplatin and intraarticular cisplatin with transcatheter arterial embolization (TAE).
  • The criteria for selecting patients for this study were as follows: age 16-75 years, stage Ib2-IV according to the classification of the International Federation of Gynecology and Obstetrics (FIGO), performance status between 0 and 2, a creatinine clearance of >40 ml/min, adequate bone marrow and adequate renal and hepatic function.
  • FIGO stage was Ib2 in seven patients, IIa in seven patients, IIb in four, IIIa in one, IIIb in seven and IVa in six.
  • Twenty-four patients had squamous cell carcinoma, three had adenocarcinoma and five had adenosquamous carcinoma.
  • Nedaplatin (30-70 mg/m2) was administered intravenously on day 1 and cisplatin (70 mg/m2) was administered intraarticularly via both uterine arteries on day 3 using the Seldinger method.
  • This course of treatment was repeated every 3 weeks for 2-3 cycles.
  • Response to the therapy was defined by magnetic resonance imaging.
  • These results show that this combination chemotherapy effected a high response rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Balloon Occlusion / methods. Cisplatin / administration & dosage. Organoplatinum Compounds / administration & dosage. Uterine Cervical Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adult. Aged. Antineoplastic Agents / administration & dosage. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12067139.001).
  • [ISSN] 0251-1649
  • [Journal-full-title] International journal of clinical pharmacology research
  • [ISO-abbreviation] Int J Clin Pharmacol Res
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ: Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1272-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
  • PURPOSE: To evaluate the outcome and patterns of failure in women with uterine clear-cell carcinoma and discuss implications for adjuvant radiation therapy (RT).
  • METHODS: Between 1980 and 2000, 686 endometrial carcinoma patients underwent primary surgery at our institution.
  • Thirty-eight women (5.5%) had clear-cell tumors (18 clear-cell only, 8 clear-cell + adenocarcinoma, and 12 clear-cell + other unfavorable histologies [10 papillary serous, 1 uterine sarcoma, 1 both]).
  • FIGO stages were as follows: 3 IA, 4 IB, 5 IC, 4 IIA, 6 IIB, 8 IIIA, 2 IIIB, 3 IIIC, and 6 IV.
  • Adjuvant therapies included the following: 5 none, 22 RT (13 pelvic RT, 2 vaginal brachytherapy, 7 both), 11 chemotherapy (8 alone, 3 after pelvic RT), and 3 hormones.
  • No correlation was seen between relapse and stage, myometrial invasion, cytology, cervical extension, or involvement of extrauterine sites.
  • Corresponding pelvic failure rates in the Stage IA-IIB patients with and without RT were 0/16 (0%) and 5/6 (83%) (p < 0.0001).
  • Only 1 (2%) patient developed an isolated abdominal failure (This patient had a mixed clear-cell/papillary serous tumor).
  • CONCLUSION: Clear-cell carcinoma comprises a small percentage of endometrial cancers, frequently presents as a mixed histology, and has a poor overall outcome.
  • Unlike papillary serous tumors, clear-cell carcinoma does not seem to have a high propensity for abdominal failure.
  • Future protocols should focus instead on combinations of locoregional RT and chemotherapy to reduce the risk of local and systemic recurrence.
  • [MeSH-minor] Abdominal Neoplasms / secondary. Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Brachytherapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cystadenocarcinoma / pathology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy. Life Tables. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / mortality. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Pelvic Neoplasms / secondary. Prognosis. Sarcoma / pathology. Treatment Failure. Treatment Outcome. Uterine Neoplasms / pathology. Vaginal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12654437.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 30
  •  go-up   go-down


26. Abali H, Eren OO, Erman M, Uner AH, Kose F, Guler N: Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: a case report. Int J Gynecol Cancer; 2003 Sep-Oct;13(5):687-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: a case report.
  • The diagnosis of cervical squamous cell carcinoma with concurrent T-cell rich B cell lymphoma in dissected lymph nodes has not been reported to our knowledge.
  • In our case, the biopsy of an exophytic lesion at the uterine cervix showed squamous cell carcinoma in a 50-year-old woman presenting with postcoital bleeding.
  • Type III hysterectomy, bilateral salpingo-oophorectemy, bilateral pelvic, para-aortic lymph node dissections were performed.
  • Pathologic examination revealed a T-cell rich B cell lymphoma in some lymph nodes beside squamous cell carcinoma in several of others.
  • The cervical carcinoma was staged as FIGO clinical stage IB1 and the lymphoma as Ann Arbor IIA.
  • Six cycles of CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolon) chemotherapy for the lymphoma and concomitant pelvic chemoradiotherapy with cisplatin for cervical cancer were given.
  • In this rare coincidence, the best available therapy for each of the diseases should be considered individually.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Lymph Nodes / pathology. Lymphoma, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Lymph Node Excision / methods. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. T-Lymphocytes / pathology. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Int J Gynecol Cancer. 2015 Jul;25(6):1142 [26098094.001]
  • (PMID = 14675356.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Duplicate Publication; Journal Article; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


27. Niibe Y, Tsunoda S, Jobo T, Imai M, Matsuo K, Matsunaga K, Unno N, Hayakawa K: Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501)--initial analysis. Eur J Gynaecol Oncol; 2008;29(3):222-4
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501)--initial analysis.
  • OBJECTIVE: Locally advanced uterine cervical carcinoma (LAUCC) treated with chemoradiotherapy is considered to be the standard treatment regimen.
  • Furthermore, the total dose of Japanese radiation therapy protocol is less than that of the USA which indicated that chemoradiotherapy for LAUCC is better than radiation therapy alone by phase III clinical trials.
  • Thus, the current phase II study was designed to evaluate chemoradiotherapy with a lower radiation dose for LAUCC using weekly nedaplatin effectively and safely in the Japanese population.
  • Nedaplatin is a platinum drug and no hydration is required to infuse patients because it is less toxic on renal function.
  • If this phase II trial is successful, chemoradiotherapy for LAUCC in out-patient clinics could be possible.
  • PATIENTS AND METHODS: Patients registered in the current study were found to have LAUCC based on the following criteria i) pathologically proven squamous cell carcinoma or adenocarcinoma, ii) FIGO clinical Stage Ib, IIa, IIb with bulky tumor (diameter > 40 mm assessed by pelvic magnetic resonance imaging) or pelvic lymph node swelling (diameter > 10 mm assessed by pelvic computed tomography);.
  • iii) FIGO clinical Stage IIIa, IIIb and IVa with no paraaortic lymph node swelling (diameter > 10 mm) observed by abdominal computed tomography;.
  • The treatment protocol was as follows: Radiation therapy in a combination of external beam radiation therapy (total dose: 50 Gy-52 Gy/25-27 fractions with central shielding after 30-32 Gy) with high-dose rate intracavitary irradiation (24-30 Gy/4-6 fractions to point A).
  • Chemotherapy applied in the current study was weekly nedaplatin infused intravenously (30 mg/mm2/time, once a week, total 150 mg/mm2/5 weeks).
  • As for clinical stage, nine were IIIb and only one was IIb.
  • Nine patients were proven to have squamous cell carcinoma and one adenocarcinoma.
  • CONCLUSIONS: This initial analysis of the phase II study confirmed that concurrent chemoradiotherapy using nedaplatin is safe and efficacious, thus we decided to undergo further studies.
  • [MeSH-major] Adenocarcinoma. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell. Organoplatinum Compounds / therapeutic use. Uterine Cervical Neoplasms

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592783.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin
  •  go-up   go-down


28. Hauspy J, Verkinderen L, De Pooter C, Dirix LY, van Dam PA: Sentinel node metastasis in the groin detected by technetium-labeled nannocolloid in a patient with cervical cancer. Gynecol Oncol; 2002 Sep;86(3):358-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node metastasis in the groin detected by technetium-labeled nannocolloid in a patient with cervical cancer.
  • OBJECTIVE: The aim of this study was to describe the first sentinel groin node metastasis detected by technetium-labeled nanocolloid in a patient with cervical carcinoma.
  • METHOD: Preoperatively, 60 mBq technetium-labeled nannocolloid was injected at 3 and 9 o'clock in the uterine cervix.
  • RESULTS: A 52-year-old diagnosed with FIGO stage IIA squamous cervical carcinoma was referred to our unit.
  • On physical examination a bulky cervical tumor and a 1.5-cm enlarged left inguinal lymph node were found.
  • As both the inguinal and the obturator lymph nodes contained metastatic deposits, the patient was treated with the combination of chemotherapy and radiotherapy.
  • CONCLUSION: Inguinal lymph nodes can rarely be the sentinel nodes in patients with cancer of the uterine cervix.
  • [MeSH-major] Carcinoma, Squamous Cell / radionuclide imaging. Lymph Nodes / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Aggregated Albumin. Uterine Cervical Neoplasms / radionuclide imaging


29. Niibe Y, Hayakawa K, Tsunoda S, Kanai T, Imai M, Arai M, Arai T, Kawaguchi M, Jobo T, Hamada Y, Yago K, Unno N, Kitasato Gynecologic Radiation Oncology Group: Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma: Kitasato Gynecologic Radiation Oncology Group (KGROG 0501). Jpn J Clin Oncol; 2007 Jan;37(1):70-2
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma: Kitasato Gynecologic Radiation Oncology Group (KGROG 0501).
  • In order to evaluate the safety and efficacy of chemoradiotherapy using nedaplatin for locally advanced uterine cervical carcinoma in Japanese patients, we have started a single-institute phase II trial.
  • Eligibility criteria include: (i) pathologically proven squamous cell carcinoma or adenocarcinoma, (ii) clinical FIGO stage Ib, IIa, or IIb with bulky tumor (> 40 mm) or pelvic lymph node swelling, or (iii) clinical FIGO stage IIIa, IIIb and IVa, (iv) no para-aortic lymph node swelling.
  • Nedaplatin (30 mg/m2) is intravenously infused on a weekly basis for five times.
  • The primary endpoint is 3-year overall survival, and the secondary endpoints are tumor response, 2-year overall survival, 3-year progression-free survival, acute adverse events, protocol treatment compliance, and late adverse events.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Organoplatinum Compounds / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Brachytherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Dose Fractionation. Female. Humans. Radiotherapy, High-Energy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204507.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin
  •  go-up   go-down


30. Kokka F, Vorgias G, Tserkezoglou A, Tsiaousi I, Hadjieleftheriou G, Andriotis M, Akrivos T, Fotiou S, Apostolikas N: Preoperative work-up of early cervical cancer (stages Ib-IIa). Eur J Gynaecol Oncol; 2003;24(2):175-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative work-up of early cervical cancer (stages Ib-IIa).
  • OBJECTIVE: To determine the effectiveness of preoperative investigations in early cervical cancer.
  • MATERIALS: We retrospectively reviewed the medical records of 309 patients with previously untreated early cervical carcinoma who completed pretreatment evaluation at "St. Savas" Cancer Hospital of Athens and "Metaxas" Memorial Hospital of Peireas between January 1986 and September 1, 2000.
  • Ages ranged from 18-77 years old with a mean age of 48 and S.D. of 12.25.
  • FIGO staging was Ib (200 pts.
  • ), IIa (105 pts.
  • Histologic type was squamous (267 pts.
  • Patients with early stage cervical carcinoma were treated with Wertheim-Meigs radical hysterectomy and pelvic lymphadenectomy, while those with advanced stage cervical carcinoma were treated with radiotherapy and chemotherapy.
  • CONCLUSION: In our series of patients with early stage cervical carcinoma, imaging and endoscopic tests added limited information over pelvic examination and altered in four cases (1.29%) the choice of the appropriate treatment modality.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Preoperative Care / methods. Urologic Diseases / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Colonoscopy. Cystoscopy. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701973.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


31. Chen SW, Liang JA, Yang SN, Lin FJ: High dose-rate brachytherapy for elderly patients with uterine cervical cancer. Jpn J Clin Oncol; 2003 May;33(5):221-8
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose-rate brachytherapy for elderly patients with uterine cervical cancer.
  • BACKGROUND: The need for radiotherapy (RT) in cancer treatment for the elderly patient is growing.
  • The purpose of this study was to analyze the efficacy and complication rate for radiotherapy, using external-beam irradiation (EBRT) and high dose-rate intracavitary brachytherapy (HDRICB), for patients aged 70 years or older with carcinoma of the uterine cervix.
  • METHODS: From September 1992 to December 1997, 295 patients diagnosed with uterine cervical cancer completed RT at the Shin Kong Memorial Hospital and China Medical College Hospital.
  • Two hundred and fifty-eight patients [International Federation of Gynecology and Obstetrics (FIGO) stage distribution: 35 Ib, 26 IIa, 122 IIb, 10 IIIa, 58 IIIb, 7 IVa] who had undergone at least two courses of HDRICB and a minimum of 3 years of follow-up, were evaluated.
  • A retrospective analysis was conducted to compare the outcome of radiation therapy for the 179 patients under 70 years of age (younger group) and the 79 patients aged 70 years or older (older group).
  • After a total EBRT dose of 40-45 Gy/20 in 25 fractions, irradiating the whole pelvis over 4-5 weeks, dosage for patients diagnosed as FIGO stage IIb-IVa bilateral parametrial disease was boosted to 54-58 Gy, with central shielding.
  • Total prescribed Point A dosages (EBRT + HDRICB) ranged from 58 to 71.6 Gy (median, 65.6 Gy) for stage IB-IIA, while for larger lesions (stage IIB-IVA) analogous dosages were 59-75.6 Gy (median, 65.6 Gy).
  • RESULTS: The respective 5-year actuarial survivals (AS) for the older and younger groups were 82/85% for stage Ib, 65/65% for IIa, 61/71% for IIb and 35/59% for IIIa-b.
  • The 5-year cause-specific survivals (CSS) for the older and younger groups were 100/95% for stage Ib, 85/75% for IIa, 78/72% for IIb and 42/61% for IIIa-b.
  • The 5-year pelvic relapse-free survivals (PRFS) for the older and younger groups were 100/100% for stage Ib, 91/93% for IIa, 91/90% for IIb and 67/80% for IIIa-b.
  • The 5-year distant metastasis-free survivals (DMFS) for older and younger groups were 100/100% for stage Ib, 92/88% for IIa, 84/73% for IIb and 55/75% for IIIa-b.
  • There was no statistically significant survival difference on comparing the two groups according to stage.
  • Twelve (15.0%) of the 79 older patients and 14 (7.8%) of the 179 younger patients developed RTOG grade 3-4 rectal complications (P = 0.12), while seven (8.9%) of the 79 older patients and 10 (5.6%) of the 179 younger patients developed RTOG grade 3-4 small bowel complications (P = 0.34).
  • CONCLUSION: Radiation therapy, consisting of a combination of EBRT and three or four fractions of HDRICB, proved to be effective for older patients.
  • Further optimization of treatment policy is essential by changing the HDRICB fractionation strategy, shortening the treatment time and designing combination drug regimens that are both effective and tolerable during radiotherapy.
  • [MeSH-major] Brachytherapy. Carcinoma, Squamous Cell / radiotherapy. Dose Fractionation. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adult. Age Factors. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / radiotherapy. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Radiation Injuries / epidemiology. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12865465.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Rath GK, Sharma DN, Julka PK, Subramani V, Bahl A, Haresh KP: Pulsed-dose-rate intracavitary brachytherapy for cervical carcinoma: the AIIMS experience. Am J Clin Oncol; 2010 Jun;33(3):238-41
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulsed-dose-rate intracavitary brachytherapy for cervical carcinoma: the AIIMS experience.
  • OBJECTIVE: The aim of present study was to analyze the results of pulsed-dose-rate (PDR) brachytherapy in patients with cervical carcinoma treated at our center.
  • METHODS: From September 2003 to September 2005, 48 patients with histopathologically proved cervical carcinoma, stages IB to IVA, were treated with PDR intracavitary radiotherapy (ICRT) and pelvic irradiation at our center.
  • Radiotherapy consisted of whole pelvis external beam radiation therapy (EBRT) with a dose of 40 Gy in 22 fractions over 4.5 weeks followed by 10 Gy in 5 fractions over 1 week with midline shielding.
  • Weekly chemotherapy (Cisplatin, 40 mg/m) was administered during the course of EBRT to suitable patients.
  • After an interval of 1 to 2 weeks, a single session of standard ICRT application was done to deliver a dose of 27 Gy to point A by PDR (hourly pulse, 70 cGy).
  • FIGO stage distribution of the patients was as follows: stage IB, 6; stage IIA, 1; stage IIB, 15; stage IIIB, 25; and stage IVA, 1.
  • Ten patients had disease recurrence (5 each in stage IIB and stage IIIB).
  • For the median follow-up period of 15 months, the actuarial recurrence-free survival in stages I to II was 82% and stages III to IV was 78%.
  • CONCLUSION: Our results reveal that PDR ICRT in combination with pelvic EBRT provides excellent pelvic disease control, survival, and low radiation related morbidity rate in the patients with cervical carcinoma.
  • [MeSH-major] Brachytherapy / methods. Carcinoma / radiotherapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Cisplatin / therapeutic use. Cobalt Radioisotopes / therapeutic use. Combined Modality Therapy. Female. Humans. India. Kaplan-Meier Estimate. Middle Aged. Particle Accelerators. Radiotherapy Dosage. Radiotherapy, High-Energy. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19841576.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Cobalt Radioisotopes; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Macchia G, Ferrandina G, Deodato F, Ruggieri V, Massaccesi M, Salutari V, Valentini V, Cellini N, Scambia G, Morganti AG: Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1). Gynecol Oncol; 2010 Aug 1;118(2):128-33
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1).
  • OBJECTIVE: To determine the recommended preoperative dose of large-field chemoradiation along with concomitant boost dose escalation on the tumor in locally advanced cervical carcinoma (LACC).
  • PATIENTS AND METHODS: A radiation dose of 40Gy over four weeks, 2Gy per fraction, was delivered to the tumor and the lymphatic drainage (planning target volume, PTV2), which encompassed a volume larger than standard (upper field border: L3 vertebra), concurrently with chemotherapy (cisplatin and 5-fluorouracil).
  • Radiation dose was escalated to the macroscopic tumor only (PTV1) with a concomitant boost strategy.
  • RESULTS: 32 patients (median age: 50 years; FIGO stage IB2: 4, IIA: 3, IIB: 21, III-IVA: 4) were enrolled.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Dose-Response Relationship, Radiation. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Preoperative Care. Radiotherapy Dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20494419.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


34. Cetina L, Garcia-Arias A, Uribe Mde J, Candelaria M, Rivera L, Oñate-Ocaña L, Coronel J, Dueñas-Gonzalez A: Concurrent chemoradiation with carboplatin for elderly, diabetic and hypertensive patients with locally advanced cervical cancer. Eur J Gynaecol Oncol; 2008;29(6):608-12
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation with carboplatin for elderly, diabetic and hypertensive patients with locally advanced cervical cancer.
  • INTRODUCTION: Chemoradiation based on cisplatin is the standard treatment of locally advanced cervical cancer, however, a subset of patients are either elderly and/or have comorbidities such as diabetes and hypertension.
  • PATIENTS AND METHODS: We reviewed the files of 59 patients with locally advanced cervical cancer who were treated with primary chemoradiation with weekly carboplatin.
  • The majority of cases were squamous cell carcinoma (88.14%), and distribution according to FIGO Stage was IB2 8.4%, IIA 13.5%, IIB 52.5%, IIIA 3.3% and IIIB 18.6%; Overall, 100% and 91% of patients completed external beam and intracavitary therapy.
  • CONCLUSIONS: Weekly carboplatin concurrent with pelvic radiation is well tolerated in patients with locally advanced carcinoma of the cervix who are older than 70 years and/or have diabetes mellitus and/or high blood pressure, however, the apparently slighty lower survival observed cautions against its routine use.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Diabetes Complications. Hypertension / complications. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy


35. Monk BJ, Tewari KS, Koh WJ: Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol; 2007 Jul 10;25(20):2952-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions.
  • Globally, cervical cancer is the second most common cause of cancer-related mortality among women causing approximately 234,000 deaths annually among developing countries and killing 40,000 in developed nations.
  • Most of these deaths occur in women with bulky or locally advanced cervical cancer, International Federation of Gynecology and Obstetrics (FIGO) stages IIB through IVA, when lesions are not amenable to high cure rates with surgery or radiation (RT).
  • The standard prescription for RT used to treat locally advanced cervical cancer has been dictated by common practice and patterns of care studies.
  • In contrast, the addition of concomitant chemotherapy to RT has been studied in a number of randomized prospective trials, which are discussed in detail.
  • When added to RT, cisplatin reduces the relative risk of death from cervical carcinoma by approximately 50% by decreasing local/pelvic failure and distant metastases.
  • In 1999, weekly intravenous cisplatin at 40 mg/m2 for 6 weeks in combination with RT was established as a new standard for the treatment of locally advanced cervical carcinoma.
  • More recently, this recommendation has been expanded to include women with FIGO stage IB2 lesions as well as those with bulky stage IIA cancers.
  • This monograph reviews the state of the art in treating locally advanced cervical cancer with combined chemotherapy and RT and discusses clinical and pathologic prognostic factors that impact cure.
  • Quality of life during and after multimodality therapy is considered as well as ongoing clinical trials and future directions.
  • [MeSH-major] Carcinoma / therapy. Combined Modality Therapy / methods. Medical Oncology / methods. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Risk. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17617527.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 102
  •  go-up   go-down


36. Abali H, Eren OO, Erman M, Uner AH, Kose F, Guler N: Coincidental detection of T-cell rich B-cell lymphoma in the paraaortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer. Int J Gynecol Cancer; 2003 Jul-Aug;13(4):548-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coincidental detection of T-cell rich B-cell lymphoma in the paraaortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer.
  • The diagnosis of cervical squamous cell carcinoma with concurrent T-cell rich B-cell lymphoma in dissected lymph nodes has not been reported to our knowledge.
  • The biopsy of an exophytic lesion at the uterine cervix showed squamous cell carcinoma in a 50-year-old woman presenting with postcoital bleeding.
  • Type III hysterectomy, bilateral salpingo-oophorectemy, bilateral pelvic, paraaortic lymph node dissections were performed.
  • Pathologic examination revealed a T-cell rich B-cell lymphoma in some lymph nodes beside squamous cell carcinoma in several of others.
  • The cervical carcinoma was staged as FIGO clinical stage IB1 and the lymphoma as Ann Arbor IIA.
  • Six cycles of CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone) chemotherapy for the lymphoma and concomitant pelvic chemo-radiotherapy with cisplatin for cervical cancer were given.
  • In this rare coincidence; the best available therapy for each of the diseases should be considered individually.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Lymph Nodes / pathology. Lymphoma, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Lymph Node Excision / methods. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. T-Lymphocytes / pathology. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12911737.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Duplicate Publication; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


37. Wong FC, Tung SY, Leung TW, Sze WK, Wong VY, Lui CM, Yuen KK, O SK: Treatment results of high-dose-rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1254-64
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of high-dose-rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens.
  • PURPOSE: To review the treatment results and complications of high-dose-rate (HDR) intracavitary brachytherapy for patients with carcinoma of the cervix in a single institute and to compare them with those of low-dose-rate (LDR) brachytherapy reported in the literature.
  • METHODS AND MATERIALS: Two hundred twenty patients with carcinoma of the cervix were treated by primary radiotherapy between 1991 and 1998.
  • The distribution according to Federation of Gynecology and Obstetrics (FIGO) staging system was as follows: Stage IB, 11.4%; IIA, 9.1%; IIB, 50.9%; IIIA, 3.6%; IIIB, 23.2%; and IVA, 1.8%.
  • They were treated with whole pelvic irradiation giving 40 Gy to the midplane in 20 fractions over 4 weeks.
  • This was followed by parametrial irradiation, giving 16-20 Gy in 8-10 fractions.
  • HDR intracavitary brachytherapy was given weekly, with a dose of 7 Gy to point A for three fractions and, starting from 1996, 6 Gy weekly for four fractions.
  • The median overall treatment time was 50 days (range 42-73 days).
  • The median follow-up time was 4.7 years (range 3 months to 11.1 years).
  • The 5-year actuarial failure-free survival (FFS) and cancer-specific survival (CSS) rates for stage IB, IIA, IIB, IIIA, IIIB, and IVA were 87.7% and 86.6%, 85% and 85%, 67.8% and 74%, 46.9% and 54.7%, 44.8% and 50.4%, 0% and 25%, respectively.
  • On multivariate analysis, young age (< 50) (p = 0.0054), adenocarcinoma (p = 0.0384), and stage (p = 0.0005) were found to be independent poor prognostic factors.
  • CONCLUSION: Our experience in treating cervical cancer with HDR intracavitary brachytherapy is encouraging.
  • Our treatment results and complication rates were compatible with those of the LDR series.
  • Further studies are eagerly awaited to better define the optimal fractionation schedule for HDR brachytherapy and the schedule on how chemotherapy may be combined with it.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, High-Energy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Combined Modality Therapy. Cystitis / etiology. Disease-Free Survival. Dose Fractionation. Enteritis / etiology. Female. Follow-Up Studies. Humans. Life Tables. Lymphatic Irradiation. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Particle Accelerators. Pelvis. Proctitis / etiology. Proportional Hazards Models. Radiation Injuries / etiology. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1159-61 [12654419.001]
  • (PMID = 12654435.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


38. Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, Avizonis V, Fromm M, Greven K: A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys; 2007 Jan 1;67(1):104-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
  • PURPOSE: To determine treatment-related acute toxicity rates in patients with locally advanced cervical cancer treated by oral celecoxib, i.v. cisplatin and 5-FU, and concurrent pelvic radiation therapy.
  • METHODS AND MATERIALS: Eligible patients on this RTOG Phase I-II study for advanced cervix cancer included FIGO Stage IIB-IVA or patients with FIGO Stage IB through IIA with biopsy proven pelvic node metastases or tumor size > or =5 cm.
  • Cisplatin (75 mg/m2) and 5-FU (1g/m2 for 4 days) were administered every 3 weeks times 3.
  • The primary end point of the study was treatment related toxicity.
  • Albeit, the toxicity was deemed excessive in this trial, the rate of toxicities was not too different compared to other recent experiences with concurrent chemoradiation for advanced cervix cancer.

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084549.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106633-03; United States / NCI NIH HHS / CA / R01 CA106633; United States / NCI NIH HHS / CA / R01 CA106633-01; United States / NCI NIH HHS / CA / CA106633-02; United States / NCI NIH HHS / CA / R01 CA106633-02; United States / NCI NIH HHS / CA / CA106633-03; United States / NCI NIH HHS / CA / R01 CA106633-04; United States / NCI NIH HHS / CA / CA106633-04; United States / NCI NIH HHS / CA / CA106633-01
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


39. Suprasert P, Srisomboon J, Charoenkwan K, Siriaree S, Cheewakriangkrai C, Kietpeerakool C, Phongnarisorn C, Sae-Teng J: Twelve years experience with radical hysterectomy and pelvic lymphadenectomy in early stage cervical cancer. J Obstet Gynaecol; 2010 Apr;30(3):294-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twelve years experience with radical hysterectomy and pelvic lymphadenectomy in early stage cervical cancer.
  • The objective of this study was to evaluate the outcome, prognostic factors and complications of early stage cervical cancer patients treated with radical hysterectomy and pelvic lymphadenectomy (RHPL).
  • The medical records of cervical cancer patients undergoing RHPL at Chiang Mai University Hospital over 12 years, between January 1995 and December 2006 were reviewed.
  • The most common histology was squamous cell carcinoma (67%) followed by adenocarcinoma (23%).
  • The distribution of FIGO staging was: stage IA 8.7%; stage IB 15.8%; stage IB1 61%; stage IB2 6.2%; and stage IIA 8.5%.
  • A total of 66.5% of patients underwent RHPL without adjuvant treatment; 12.1% received neoadjuvant chemotherapy.
  • Stage IB2/IIA, non-squamous cell carcinoma, nodal involvement and positive vaginal margins were independent, significant, poor prognostic factors.
  • It was concluded that early stage cervical cancer patients treated with RHPL have long-term favourable outcome with minimal morbidity.
  • Stage IB2 and IIA, non-squamous cell carcinoma, nodal and vaginal involvement were independent adverse prognostic factors.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Hysterectomy. Lymph Node Excision. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Connective Tissue / pathology. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Proportional Hazards Models. Young Adult

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20373935.001).
  • [ISSN] 1364-6893
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Huang CY, Chen YL, Chu TC, Cheng WF, Hsieh CY, Lin MC: Prognostic factors in women with early stage small cell carcinoma of the uterine cervix. Oncol Res; 2009;18(5-6):279-86
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in women with early stage small cell carcinoma of the uterine cervix.
  • Small cell carcinoma of the uterine cervix (SCCUC) is an uncommon, aggressive disease accounting for less than 5% of all cervical cancers.
  • Due to its rarity, definitive treatment strategies have not been developed.
  • Our aim was to analyze the clinical factors, treatment modalities, sites of relapse, and overall survival of women with early stage SCCUC and thus determine prognostic factors.
  • The clinical records of 18 women diagnosed with stage IB1 to IIA SCCUC were reviewed, and patient characteristics and treatment modalities were analyzed to determine the prognostic factors for disease-free survival (DFS) and overall survival (OS).
  • International Federation of Gynecology and Obstetrics (FIGO) stage and lymph node metastasis were significant prognostic factors of OS as determined by multivariate analysis (p < 0.05).
  • Radical hysterectomy followed by adjuvant chemotherapy resulted in higher 2-year survival rates compared to radical hysterectomy followed by adjuvant radiotherapy (62.5% vs. 16.7%); however, the difference was not statistically significant due to the small sample size.
  • FIGO stage and lymph node metastasis are significant indicators of OS in patients with early stage SCCUC.
  • Further larger scale analysis is warranted to determine whether adjuvant chemotherapy may facilitate a better prognosis than adjuvant radiotherapy.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20225765.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Yalman D, Aras AB, Ozkök S, Duransoy A, Celik OK, Ozsaran Z, Haydaroğlu A: Prognostic factors in definitive radiotherapy of uterine cervical cancer. Eur J Gynaecol Oncol; 2003;24(3-4):309-14
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in definitive radiotherapy of uterine cervical cancer.
  • PURPOSE: To determine the prognostic factors related to local control and survival in 257 patients with uterine cervical cancer treated with definitive radiotherapy (RT).
  • MATERIALS AND METHODS: The medical records of 257 patients treated with definitive RT from January 1987 to December 1998 were reviewed retrospectively.
  • Pretreatment and treatment parameters were analyzed to determine their prognostic value onlocal control and survival.
  • Squamous cell carcinoma was the most common histologic type (89.1%).
  • The distribution per FIGO Stage was IIA: 13.2%; IIB: 54.9%; IIIA: 3.9%; IIIB: 19.8%; IVA: 8.2%.
  • Ninety-eight patients (38.1%) were treated with external RT alone; 134 (52.1%) received both external RT and intracavitary brachytherapy; 21 (8.2%) received external RT and chemotherapy and four (1.6%) received external RT, intracavitary brachytherapy and chemotherapy.
  • In univariate analysis the prognostic factors identified for local progression-free survival were histology (p = 0.008), FIGO stage (p < 0.001), initial hemoglobin (Hgb) level (p = 0.001), total radiation dose (p = 0.039), use of brachytherapy (p = 0.001) and of chemotherapy (p = 0.037) and enlarged paraaortic nodes (p = 0.016).
  • In multivariate analysis the prognostic factors were FIGO stage (p = 0.014), initial Hgb level (p = 0.040), and use of brachytherapy (p = 0.013).
  • The prognostic factors identified for disease-free survival were histology (p = 0.011), FIGO stage (p < 0.001), initial Hgb level (p < 0.001), use of brachytherapy (p = 0.001) and of chemotherapy (p = 0.014) in univariate analysis; and FIGO stage (p < 0.001), initial Hgb level (p = 0.017), total tumor dose (p = 0.034), use of brachytherapy (p = 0.006) and of chemotherapy (p = 0.021) in multivariate analysis.
  • Factors influencing overall survival were FIGO stage (p < 0.001), initial Hgb level (p = 0.006), overall treatment time (p = 0.028), total tumor dose (p = 0.007), use of brachytherapy (p < 0.001), enlarged paraaortic (p < 0.001) and pelvic nodes (p = 0.004) in univariate analysis; and FIGO stage (p < 0.001), overall treatment time (p = 0.031), enlarged paraaortic (p = 0.007) and pelvic lymph nodes (p = 0.043) in multivariate analysis.
  • CONCLUSION: Definitive RT is an effective treatment for patients with uterine cervical cancer.
  • There are many prognostic factors influencing treatment outcome.
  • Brachytherapy and chemotherapy must be added in appropriate patients to improve the outcome.
  • Future prospective trials should be undertaken to confirm the validity of these factors and to individualize the treatment strategy for every patient.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Analysis of Variance. Biopsy, Needle. Disease-Free Survival. Dose-Response Relationship, Radiation. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12807246.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


42. Pang LC: Solitary recurrent metastasis of squamous cell carcinoma of the uterine cervix in the spleen: case report. South Med J; 2004 Mar;97(3):301-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary recurrent metastasis of squamous cell carcinoma of the uterine cervix in the spleen: case report.
  • In cervical squamous cell carcinoma, solitary metastasis to and recurrence in the parenchyma of the spleen are uncommon in the absence of apparent disease in other sites.
  • A case of a 50-year-old patient with a Stage IIa carcinoma of the cervix treated with radical hysterectomy and pelvic lymphadenectomy followed by radiotherapy is reported.
  • Serial squamous cell carcinoma (SCC) antigen measurements have been performed for monitoring the course of disease, response to treatment, and detection of tumor recurrence.
  • Recurrent disease was initially suspected on the basis of an elevated SCC level, 7.11 microg/ml (normal, < 1.5 microg/ml), subsequently confirmed by computed tomographic scan, magnetic resonance imaging, and positron emission tomography of the abdomen and pelvis.
  • Laparoscopic splenectomy followed by chemotherapy with cisplatin was performed.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Splenic Neoplasms / secondary. Uterine Cervical Neoplasms / secondary






Advertisement